iTeos Therapeutics Announces $120 Million Registered Direct Offering [Yahoo! Finance]
iTeos Therapeutics, Inc. (ITOS)
Company Research
Source: Yahoo! Finance
Further strengthens balance sheet with pro forma cash position of $715 million, extending anticipated runway through 2027 WATERTOWN, Mass. and GOSSELIES, Belgium, May 10, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that it has entered into a securities purchase agreement to sell 1,142,857 shares of the Company's common stock (the “Common Stock”) at a price of $17.50 per share, representing a premium of approximately 44% to iTeos' closing price on May 9, 2024 and pre-funded warrants to purchase up to 5,714,285 shares of the Common Stock (the “Pre-Funded Warrants”) at a price of $17.499 per pre-funded warrant, in a registered direct offering. Each pre-funded warrant will have an exercise price of $0.001 per share, will be exercisable immediately, and will be exercisable until exercised in f
Show less
Read more
Impact Snapshot
Event Time:
ITOS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ITOS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ITOS alerts
High impacting iTeos Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ITOS
News
- iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its price target raised by analysts at HC Wainwright from $44.00 to $46.00. They now have a "buy" rating on the stock.MarketBeat
- iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates [Yahoo! Finance]Yahoo! Finance
- iTeos Reports First Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewswire
- iTeos Therapeutics Announces $120 Million Registered Direct OfferingGlobeNewswire
- iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024 [Yahoo! Finance]Yahoo! Finance
ITOS
Earnings
- 5/10/24 - Miss
ITOS
Sec Filings
- 5/15/24 - Form SC
- 5/14/24 - Form 4
- 5/14/24 - Form SC
- ITOS's page on the SEC website